Table 1. Baseline characteristics of 48 HIV-infected children enrolled into the study.
| Age in months (median, range) | 147 (29–241) | |
| Male/female ratio | 0.5 | |
| HIV immunologic stage (n, %) | ||
| 1 (normal CD4 lymphocyte count) | 14 (29%) | |
| 2 (moderately immunosuppressed) | 12 (25%) | |
| 3 (severely immunosuppressed) | 22 (46%) | |
| Current CD4+ T cell frequency (n, %) | ||
| ≥ 25% (normal) | 34 (71%) | |
| 15–24% (moderately immunosuppressed) | 8 (16%) | |
| <15% (severely immunosuppressed) | 6 (13%) | |
| Current viral load (n, %) | ||
| Undetectable | 16 (33%) | |
| Up to 10,000 copies/mL | 20 (42%) | |
| >10,000 copies/mL | 12 (25%) | |
| Participants receiving antiretroviral therapy (n, %) | 46 (96%) | |
| HIV clinical stage (n, %) | Given | Current |
| N (asymptomatic) | 6 (12%) | 22 (46%) |
| A (mildly symptomatic) | 11 (22%) | 7 (15%) |
| B (moderately symptomatic) | 15 (31%) | 6 (12%) |
| C (AIDS) | 16 (33%) | 13 (27%) |
“HIV immunologic stage” refers to the CDC immunologic classification of the patient, which reflects their nadir CD4+ T cell frequency, and may be different from their “current CD4+ T cell frequency”. “Given” HIV clinical stage refers to participants' CDC classification of symptomatic disease [24]. “Current” HIV clinical stage reflected application of the CDC classification to symptomatic disease at the time of study enrollment. The latter classification was useful because “given” HIV clinical disease stage often reflected previous, severe disease, while many participants on HAART were clinically well at the time of enrollment.